2014
DOI: 10.1016/s0168-8278(14)61218-6
|View full text |Cite
|
Sign up to set email alerts
|

P1058 Long-Term Efficacy of Tenofovir in Previously Treated and Naive Patients. Results From the Spanish Chronic Hepatitis B Registry (Ciberhep)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
4
0

Year Published

2014
2014
2018
2018

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(4 citation statements)
references
References 0 publications
0
4
0
Order By: Relevance
“…69 During 3-4 years of TDF treatment in HBeAg-negative CHB patients in real practice, the virological response rates ranged from 92% to 100% without the emergence of TDF resistance, while 75% of patients had normalised ALT. [70][71][72][73] No HBeAg-negative CHB patient cleared HBsAg wihin the first year of ETV or TDF therapy and very few ($1%) achieved this endpoint during long-term (8 years) therapy.…”
Section: Hbsagmentioning
confidence: 99%
“…69 During 3-4 years of TDF treatment in HBeAg-negative CHB patients in real practice, the virological response rates ranged from 92% to 100% without the emergence of TDF resistance, while 75% of patients had normalised ALT. [70][71][72][73] No HBeAg-negative CHB patient cleared HBsAg wihin the first year of ETV or TDF therapy and very few ($1%) achieved this endpoint during long-term (8 years) therapy.…”
Section: Hbsagmentioning
confidence: 99%
“…The long‐term follow‐up of the TDF‐registration trial reported that 99% of the 375 HBeAg negative patients achieved undetectable HBV DNA after 7 years, with no evidence of TDF‐resistance but only one patient achieved HBsAg seroclearance at year 5 . Four European field practice studies including 1597 CHB patients (mean age 47 years old, 75% HBeAg negative, 26% with cirrhosis) reported that a 3‐ to 4‐year course of TDF achieved virological response rates ranging from 92 to 100% with no TDF‐resistance (Fig. ).…”
Section: Nucleos(t)ides Analoguesmentioning
confidence: 99%
“…Four European field practice studies including 1597 CHB patients (mean age 47 years, 75% HBeAg negative, 26% with cirrhosis) reported that a 3‐4 year course of TDF treatment achieved virological response rates ranging from 92% to 100% without emergence of TDF‐R (Figure ).…”
Section: Virological Biochemical and Serological Responsesmentioning
confidence: 99%
“…Moreover, this endpoint is rarely achieved (~1%) in HBeAg‐negative patients or in HBeAg‐positive patients infected at birth. On the other hand, in NUC‐treated HBeAg‐positive patients with good predictors of response, such as short duration of infection, genotype A, elevated ALT levels and moderate levels of HBV DNA, this endpoint can be achieved in up to 20% of the patients after 5 years of treatment . This is important because the best stopping rule for NUC‐treated patients is HBsAg loss and anti‐HBs seroconversion, and the latter is the only safe stopping rule in patients with cirrhosis.…”
Section: Virological Biochemical and Serological Responsesmentioning
confidence: 99%